Kiniksa Pharmaceuticals International Plc (KNSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 423,239 | 270,259 | 220,180 | 38,544 | 0 |
| Cost of Goods | 60,910 | 33,407 | 22,895 | 9,100 | N/A |
| Gross Profit | 362,329 | 236,852 | 197,285 | 29,444 | N/A |
| Operating Expenses | 408,855 | 262,455 | 188,407 | 186,180 | 157,363 |
| Operating Income | -45,616 | -25,196 | 9,773 | -156,636 | -157,363 |
| Other Income | 9,464 | 8,544 | 1,253 | 97 | 1,134 |
| Pre-tax Income | -36,152 | -16,652 | 11,026 | -156,539 | -156,229 |
| Income Tax | 7,041 | -30,736 | -172,337 | 1,385 | 5,152 |
| Net Income Continuous | -43,193 | 14,084 | 183,363 | -157,924 | -161,381 |
| Net Income | $-43,193 | $14,084 | $183,363 | $-157,924 | $-161,381 |
| EPS Basic Total Ops | -0.60 | 0.20 | 2.64 | -2.30 | -2.61 |
| EPS Basic Continuous Ops | -0.60 | 0.20 | 2.64 | -2.30 | -2.61 |
| EPS Diluted Total Ops | -0.60 | 0.20 | 2.60 | -2.30 | -2.61 |
| EPS Diluted Continuous Ops | -0.60 | 0.20 | 2.60 | -2.30 | -2.61 |
| EPS Diluted Before Non-Recurring Items | -0.60 | -0.34 | 2.60 | -2.30 | -2.61 |
| EBITDA(a) | $-43,921 | $-22,855 | $12,175 | $-154,281 | $-154,958 |